New Products: Etravirine (Intelence)


The latest in medical products for obstetrics and gynecology.

After a priority review, the FDA has approved etravirine tablets (Intelence) to treat HIV infection in adults who have failed therapy with other antivirals. A nonnucleoside reverse transcriptase inhibitor (NNRTI) that helps to block an enzyme HIV needs to multiply, the drug was approved to be used with other active anti-HIV drugs. When taken as prescribed, etravirine reduces the amount of HIV in the blood and increases white blood cells that help fight off other infections. It may also reduce the risk of death or some infections.

The approval was based chiefly on data from 599 adults who received etravirine in two randomized double-blind, placebo-controlled trials. For more information on the trials, adverse events, and use in pregnancy, visit

Related Videos
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:
Enhancing cervical cancer management with dual stain | Image Credit:
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit:
Understanding the impact of STIs on young adults | Image Credit:
CDC estimates of maternal mortality found overestimated | Image Credit:
Study unveils maternal mortality tracking trends | Image Credit:
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit:
Unveiling gender disparities in medicine | Image Credit:
Exploring the intersection of heart health and women's health | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.